Published by Ministry of Health, Labour and Welfare

()

Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this

English translation, the former shall prevail.

Revision of Precautions Freeze-dried BCG vaccine (for percutaneous use)

August 22, 2019

Therapeutic category

Vaccines

Non-proprietary name Freeze-dried BCG vaccine

Safety measure Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u> Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Adverse Reactions	Adverse Reactions
Clinically Significant Adverse Reactions	Clinically Significant Adverse Reactions
Systemically disseminated BCG infection:	BCG infection:
When individuals with immunodeficiency syndrome are vaccinated,	Meningitis, osteitis, osteomyelitis, or periostitis may occur. When
BCG may be disseminated in the bloodstream to the whole body	individuals with immunodeficiency syndrome are vaccinated, BCG
and produce a miliary tuberculosis-like lesion.	may be disseminated in the bloodstream to the whole body and
(When systemically disseminated BCG infection is suspected,	produce miliary tuberculosis-like lesions, resulting in systemically
appropriate measures should be taken immediately, such as	disseminated BCG infection. When BCG infection is suspected,
administration of anti-tuberculous drugs.)	appropriate measures should be taken immediately, such as
Osteitis, osteomyelitis, periostitis:	administration of anti-tuberculous drugs.
Osteitis, osteomyelitis, and periostitis may occur.	
(When osteitis, osteomyelitis, or periostitis is suspected,	
appropriate measures should be taken, such as administration of	
anti-tuberculous drugs.)	

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>